Compare Revvity Inc (RVTY) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Revvity Inc trades at $115.72 (market cap $12.91B), while Virgin Galactic Holdings, Inc. trades at $3.3 (market cap $498.02M). The key difference: Revvity Inc is far larger — about 25.9× Virgin Galactic Holdings, Inc.'s market cap, and Revvity Inc pays a 0.24% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| RVTY | SPCE | |
|---|---|---|
Market Cap | $12.91B | $498.02M |
Sector | Technology | Industrials |
52-Week High | $117.75 | $7.52 |
52-Week Low | $82.26 | $2.17 |
Enterprise Value | $15.23B | $597.87M |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Virgin Galactic (SPCE) trades at $3.275, up 1.39% on the day, with a bullish technical signal from moving averages. The company continues to report significant losses, with a net income margin of -19,781.3% and negative cash flow from operations of $240.14M in 2025. Recent quarters have seen earnings beats against low expectations. Analyst sentiment is mixed, with a Buy/Hold/Sell split of 29.41%/41.18%/29.41% among 17 analysts.
The outlook remains highly speculative, driven by progress in commercial spaceflight operations against persistent financial losses. Investment opportunity hinges on successful scaling and future revenue generation, but risks include cash burn, high debt, and intense competition in the space sector. The stock is suitable only for risk-tolerant investors betting on long-term commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
